InDex Pharmaceuticals Holding AB (publ)

OM:INDEX Stock Report

Market Cap: SEK 286.6m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

InDex Pharmaceuticals Holding Balance Sheet Health

Financial Health criteria checks 6/6

InDex Pharmaceuticals Holding has a total shareholder equity of SEK236.0M and total debt of SEK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are SEK280.9M and SEK44.9M respectively.

Key information

0%

Debt to equity ratio

SEK 0

Debt

Interest coverage ration/a
CashSEK 269.82m
EquitySEK 235.98m
Total liabilitiesSEK 44.92m
Total assetsSEK 280.90m

Recent financial health updates

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13
Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Jul 11
We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Jan 21
We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Aug 31
We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

Mar 29
Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

Feb 04
InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Dec 21
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Financial Position Analysis

Short Term Liabilities: INDEX's short term assets (SEK278.4M) exceed its short term liabilities (SEK43.6M).

Long Term Liabilities: INDEX's short term assets (SEK278.4M) exceed its long term liabilities (SEK1.3M).


Debt to Equity History and Analysis

Debt Level: INDEX is debt free.

Reducing Debt: INDEX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INDEX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: INDEX has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 0.2% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/10 08:30
End of Day Share Price 2024/06/10 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

InDex Pharmaceuticals Holding AB (publ) is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arvid NecanderCarnegie Investment Bank AB
Filip EinarssonRedeye